78 Johnson & Johnson to acquire $2 billion drug developer "Ambrx Biopharma" to treat Turbo Cancers with same tech as Pfizer's $43 billion Seagen acquisition. Both set their sights on 2025 Cancer TSUNAMI (twitter.com) 🤢 These people are sick! 🤮 posted 313 days ago by brain_dead 313 days ago by brain_dead +78 / -0 20 comments share 20 comments share save hide report block hide replies
Plus you are NOT allowed to purchase in U.S the actual cure of cancer by blocking the import.
Check out https://scienceblogs.com/insolence/2017/09/25/rigvir-a-cancer-cure-imported-from-latvia-that-cancer-patients-should-avoid
I had not heard about that one. Thanks!
You are welcome.